ArticleThoracic cancer2025

Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.

Hiroaki Kodama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.